

Cover Story
Free
By Alexandria Carolan
A sense of foreboding descended on Narjust Duma as she sat at a presentation on drug-induced toxicities. The year was 2018, Duma was a 31-year-old second-year fellow at Mayo Clinic, and her discomfort stemmed from something other than the subject matter discussed.
In Brief


Clinical Roundup
Drugs & Targets
Trending Stories
- Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- Early-onset colorectal cancer is behaving like a new, biologically distinct disease, researchers note
One woman’s pregnancy shows how this distinction matters - Cancer patients with Medicare Advantage have access to fewer providers than Medicare patients, cross-sectional study finds
- Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data in ACS guideline support greater use of noninvasive tests to ease system strain, save lives - More than 50 million Americans remain unscreened for colon cancer
New guidelines offer another option - A new diagnostic lens—and a lasting scientific legacy














